J Med Life Sci > Volume 12(2); 2015 > Article
Journal of Medicine and Life Science 2015;12(2):39-43.
DOI: https://doi.org/10.22730/jmls.2015.12.2.39    Published online December 18, 2018.
신경계질환에서 면역글로불린정맥주사
Intravenous immunoglobulins in neurological diseases
Sa-Yoon Kang
Correspondence:  Sa-Yoon Kang,
Intravenous immunoglobulin (IVIg) has been used for nearly three decades, and is proving to be an efficient anti-inflammatory and immunomodulatory treatment for a number of neurological diseases. Evidence from randomized controlled clinical trials has established IVIg as a first-line therapy for chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, and multifocal motor neuropathy and the efficacy and safety of IVIg treatment have been summarized in Cochrane systemic reviews. Reports about successful IVIg treatment in other neurological condition exist, but its use remains investigational. IVIg is an effective rescue therapy in exacerbations of myasthenia gravis and is beneficial as a second-line therapy for dermatomyositis and stiff-person syndrome. IVIg has been tested in some neurodegenerative diseases, but a controlled study in Alzheimer disease yielded disappointing results. Despite its widespread use and therapeutic success, the mechanisms of action of IVIg are poorly understood. In addition, questions remain regarding the dose, timing and duration of IVIg treatment in neurological diseases. This review highlights emerging data on the mechanisms of action of IVIg and practical guidelines on administration of IVIg in diverse neurological diseases.
Key Words: Evidence, Inflammatory, Intravenous immunoglobulin, Neurological disease, Treatment
METRICS Graph View
  • 0 Crossref
  •  0 Scopus
  • 883 View
  • 1 Download
Related articles

Editorial Office
102, Jejudaehak-ro, Jeju-si, Jeju-do 63243, Republic of Korea
Tel: +82-64-754-8023    E-mail: jmls.jeju@gmail.com                

Copyright © 2024 by Jeju National University Institute for Medical Science.

Developed in M2PI

Close layer
prev next